biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Company profile
Ticker
BMRN
Exchange
Website
CEO
Jean-Jacques Bienaime
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
BioMarin Commercial Ltd • BioMarin International Ltd ...
IRS number
680397820
BMRN stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
24 May 24
8-K
Cost Associated with Exit or Disposal Activities
14 May 24
10-Q
2024 Q1
Quarterly report
26 Apr 24
8-K
BioMarin Reports Record Financial Results for the First Quarter 2024
24 Apr 24
8-K
Other Events
23 Apr 24
ARS
2023 FY
Annual report to shareholders
9 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
22 Feb 24
Transcripts
BMRN
Earnings call transcript
2024 Q1
24 Apr 24
BMRN
Earnings call transcript
2023 Q4
22 Feb 24
BMRN
Earnings call transcript
2023 Q3
1 Nov 23
BMRN
Earnings call transcript
2023 Q2
31 Jul 23
BMRN
Earnings call transcript
2023 Q1
26 Apr 23
BMRN
Earnings call transcript
2022 Q4
28 Feb 23
BMRN
Earnings call transcript
2022 Q3
27 Oct 22
BMRN
Earnings call transcript
2022 Q2
4 Aug 22
BMRN
Earnings call transcript
2022 Q1
28 Apr 22
BMRN
Earnings call transcript
2021 Q4
24 Feb 22
Latest ownership filings
SC 13G/A
VANGUARD GROUP INC
10 Jul 24
SC 13G/A
BlackRock Inc.
8 Jul 24
4
Brian Mueller
1 Jul 24
4
ELAINE J HERON
4 Jun 24
4
RICHARD A MEIER
4 Jun 24
144
Notice of proposed sale of securities
4 Jun 24
4
Brian Mueller
31 May 24
144
Notice of proposed sale of securities
31 May 24
4
George Eric Davis
30 May 24
144
Notice of proposed sale of securities
30 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 747.00 mm | 747.00 mm | 747.00 mm | 747.00 mm | 747.00 mm | 747.00 mm |
Cash burn (monthly) | 2.71 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 10.48 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 736.52 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 271.7 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
90.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 526 |
Opened positions | 172 |
Closed positions | 63 |
Increased positions | 134 |
Reduced positions | 142 |
13F shares | Current |
---|---|
Total value | 13.10 tn |
Total shares | 171.70 mm |
Total puts | 1.73 mm |
Total calls | 1.72 mm |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 18.12 mm | $1.58 tn |
BLK Blackrock | 14.48 mm | $1.26 tn |
Dodge & Cox | 13.99 mm | $1.22 tn |
CAFBX Amcap Fund | 10.18 mm | $866.57 mm |
STT State Street | 6.90 mm | $602.23 bn |
Capital Research Global Investors | 6.52 mm | $569.51 bn |
Viking Global Investors | 6.42 mm | $560.40 bn |
AMP Ameriprise Financial | 5.40 mm | $471.95 bn |
BCS Barclays | 5.25 mm | $458.93 mm |
UBS UBS Group AG - Registered Shares | 5.06 mm | $441.63 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Jun 24 | Mueller Brian | Common Stock | Payment of exercise | Dispose F | No | No | 82.33 | 588 | 48.41 k | 71,571 |
3 Jun 24 | Meier Richard A | Common Stock | Payment of exercise | Dispose F | No | No | 76.41 | 5,451 | 416.51 k | 120,776 |
3 Jun 24 | Meier Richard A | Common Stock | Option exercise | Acquire M | No | No | 63.1 | 6,600 | 416.46 k | 126,227 |
3 Jun 24 | Meier Richard A | Stock Option (Right to Buy Common Stock) Common Stock | Option exercise | Dispose M | No | No | 63.1 | 6,600 | 416.46 k | 0 |
3 Jun 24 | Heron Elaine J | Common Stock | Payment of exercise | Dispose F | No | No | 76.41 | 4,168 | 318.48 k | 97,720 |
3 Jun 24 | Heron Elaine J | Common Stock | Option exercise | Acquire M | No | No | 63.1 | 5,047 | 318.47 k | 101,888 |
3 Jun 24 | Heron Elaine J | Stock Option (Right to Buy Common Stock) Common Stock | Option exercise | Dispose M | No | No | 63.1 | 5,047 | 318.47 k | 0 |
30 May 24 | Mueller Brian | Common Stock | Sell | Dispose S | No | Yes | 75.19 | 5,000 | 375.95 k | 72,159 |
30 May 24 | Mueller Brian | Common Stock | Option exercise | Acquire M | No | Yes | 63.1 | 5,000 | 315.50 k | 77,159 |
30 May 24 | Mueller Brian | Stock Option (Right to Buy Common Stock) Common Stock | Option exercise | Dispose M | No | No | 63.1 | 5,000 | 315.50 k | 0 |
News
Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Maintains $89 Price Target
25 Jul 24
U.S. FDA Approves BioMarin's BRINEURA For Children Under 3 Years With CLN2 Disease
24 Jul 24
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
22 Jul 24
Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
22 Jul 24
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
18 Jul 24
Press releases
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
24 Jul 24
Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval
17 Jul 24
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
11 Jul 24
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health
17 Jun 24
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
17 Jun 24